Pacific Biosciences of California NASDAQ: PACB is maintaining its existing strategy while sharpening

In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.38, indica

Pacific Biosciences of California, Inc. (PACB) Presents at Morgan Stanley 24th Annual Global Healthc

UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and low

Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million.

On July 30, 2026, the Board of Directors (the "Board") of the Company approved a restructuri

Pacific Biosciences (NASDAQ:PACB) lowers FY2026 sales outlook from $165.000 million-$175.000 million

Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of hi

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.14) per share which missed the an

On Wednesday, June 10, 2026, Ark Invest sold $7.8M in Robinhood shares Wednesday while adding 141,50

Collaboration with PacBio will generate long-read bulk RNA-seq data to advance patient-level predict

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and

Pacific Biosciences (NASDAQ:PACB) sees FY2026 sales of $165.000 million-$175.000 million vs $173.371

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal

The protocol will be formally presented at the upcoming American Association for Cancer Research (AA

Barclays analyst Luke Sergott downgrades Pacific Biosciences (NASDAQ:PACB) from Equal-Weight to U

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod

PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno

PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today ann

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, ann

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Equal-Weight and

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral

Stephens & Co. analyst Mason Carrico maintains Pacific Biosciences (NASDAQ:PACB) with a Overw

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.12) per share which beat the anal

PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno

PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today anno

Ark Invest made significant trades involving PLTR, AMD, PACB, and DASH. They sold Palantir and bough

The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to d

MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long-read sequencing solut

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod

PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, tod

Piper Sandler analyst David Westenberg maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral

Pacific Biosciences (NASDAQ:PACB) reported quarterly losses of $(0.13) per share which beat the anal

PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, toda

New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic c